




STATE MEDICAID P&T COMMITTEE MEETING

Thursday, August 21, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 125



MINUTES

Committee Members Present:

Lisa Hunt, R.Ph.
Kort Delost, R.Ph.
Julia Ozbolt, M.D.

Jameson Rice, Pharm.D.
Beth Johnson, R.Ph

Committee Members Excused:

Roger Martenau, M.D.
Ellie Brownstein, M.D.

Elizabeth Young, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Richard Sorenson, RN
Trevor Smith, CPhT

Tim Morley, R.Ph.
Robyn Seely, Pharm.D.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Cody Ball, Select Health
Betty Chan, Gilead
Laura Litzenberger, Janssen
Scott Larson, BMS
Paul Bonham, NovoNordisk

Gary Oderda, UofU
Kim Eggert, Gilead
Lori Howard, Bayer
Natalia Ruiz, UofU

Meeting conducted by: Lisa Hunt

1. **Review and Approval of July Minutes:** Minutes for July were reviewed. Julia Ozbolt made a motion to approve the July minutes, Jameson Rice seconded the motion. All in favor.
2. **Housekeeping:** Lisa Hunt reminded people in attendance today to sign in. Lisa also reported that she is going to begin in looking at bids for supplemental rebates for 2015.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the DUR board reviewed PPI drugs in the last meeting, which they will finish up during the September meeting. Also planned for discussion during the September meeting is an update to Synagis criteria and topical immunomodulator agents. She said that the Hepatitis C criteria sheets are finalized from DUR decision. A copy of the criteria is included in the P&T committee members' packets.

4. **Hepatitis C agents (Sovaldi & Olysio):** Melissa Archer presented a review of the hepatitis C agents (Sovaldi & Olysio) drug class. She presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

5. **Public Comments**

- a. Laura Litzenberger (Jansen, Olysio) – She answered questions about genotype prevalence in the United States, and discussed photo sensitivity that can occur with use.
- b. Betty Chan (Gilead, Sovaldi) – She discussed the genotypes that Sovaldi is indicated for and offered to answer questions from the committee.

6. **Committee discussion**

- a. Tim Morley asked if there is any data about genotypes being exclusive to certain demographics. Melissa Archer said that there isn't data about the demographics, the genotypes are spread out more geographically around the world. She said that genotype one is most common in the USA.
- b. Lisa Hunt said that the expected number of cases is a result of the baby boomer population. Melissa Archer said that the result of the high amount of baby boomers who received the disease from blood transfusions before modern techniques were introduced to eliminate these contaminations.
- c. Lisa Hunt presented the Other States Report to compare PDL and clinical authorization criteria from other States.
- d. Tim Morley asked about what the most common side effects are with the drugs.
- e. Melissa Archer answered saying that headache and fatigue are the two most frequently reported. She said these side effects are much less severe than the earlier treatments for Hepatitis C.
- f. Lisa Hunt commented saying that there was mention of the unlabeled uses for the Hepatitis C products, but the charge for the P&T committee is only looking for inclusion in the PDL, not for labeled uses.
- g. Beth Johnson said that this class is difficult to review when comparing equally safety and effectiveness because of the different genotypes that the two agents will be effective against.
- h. Lisa Hunt said that this is the case for all classes, because there will always be some drugs that will be more effective for a specific disease type or demographic. She said that the drugs will have a clinical PA on them to watch for proper use for safety and efficacy concerns, including looking for the genotype. The P&T committee will only look to include them on a PDL.
- i. The committee asked if previous treatment is required prior to using the products as the criteria PA language is confusing. Robyn Seely said that the criteria is only asking for a list of what therapies have been tried in the past; there is no requirement for a previous treatment.
- j. Jameson Rice makes a motion saying that the two agents are equally safe for PDL consideration. Julia Ozbolt seconds the motion. All in favor.
- k. Beth Johnson said that the drugs are effective, but not equally in treating the safe indications. She said that she thinks the drugs should be on the PDL.

1. Beth Johnson made a motion that the drugs Sovaldi and Olysio are equally effective for approved indications for consideration for inclusion on the PDL. Jameson Rice seconds. All in favor.

7. **Meeting Adjourned**

8. Next meeting is scheduled for September 18, 2014. Amebicide anti-infective and macrolide antibiotics agents will be discussed.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov